Drug Trial Radar · NCT03657043
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
Last checked: Nov 20, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
Mar 20, 2019
Primary completion
Feb 8, 2022
Study completion Feb 8, 2022
Sponsor
- Lead sponsor
- Seagen Inc.Pfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Genmab
- First posted
- Sep 4, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will study tisotumab vedotin to find out what its side effects are and to see if it works for platinum-resistant ovarian cancer (PROC). It will test different doses of tisotumab vedotin that are given at different times. It will also compare the side effects and ability to treat tumors of these different doses and schedules. In this study, there will be a safety run-in group of approximately 12 patients that will look at a dose-dense treatment schedule. In a dose-dense schedule, smaller doses are given more frequently. In addition to the safety run-in patients, there will be three groups in the study. One group will get tisotumab vedotin once every 3 weeks (21-day cycles). The two other groups will get tisotumab vedotin once a week for 3 weeks followed by 1 week off (28-day cycles).
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
Interventions
tisotumab vedotinDrug
Intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-Limiting Toxicities (DLTs) (Safety Run-In Only)Time frame: Up to 28 days
- Confirmed Objective Response Rate (ORR) (Part B)Time frame: Up to 9.7 months
Locations
37 sites in 6 countries. Site status is shown where the registry gives one.
Stanford Cancer Center South Bay
San Jose, California
Poudre Valley Health System (PVHS)
Fort Collins, Colorado
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida
Miami Cancer Institute- Plantation (MCIP)
Miami, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Augusta University
Augusta, Georgia
University of Kansas Cancer Center
Westwood, Kansas
Karmanos Cancer Institute / Wayne State University
Detroit, Michigan
University of Missouri Healthcare / Ellis Fischel Cancer Center
Columbia, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Mount Sinai Chelsea
New York, New York
Mount Sinai Medical Center
New York, New York
Columbia University Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Cleveland Clinic Fairview Hospital
Cleveland, Ohio
Cleveland Clinic, The
Cleveland, Ohio
Ohio State University Clinical Trials Management Office
Columbus, Ohio
Cleveland Clinic Hillcrest Hospital
Mayfield Heights, Ohio
Texas Oncology - Fort Worth
Dallas, Texas
Renovatio Clinical
The Woodlands, Texas
University of Virginia
Charlottesville, Virginia
Algemeen Ziekenhuis Maria Middelares
Ghent, Other, Belgium
Universitair Ziekenhuis Leuven
Lueven, Other, Belgium
Aalborg Universite Hospital
Aalborg, Other, Denmark
Mater Private
Dublin, Other, Ireland
Cork University Hospital
Wilton, Other, Ireland
Ospedale Ramazzini di Carpi
Carpi, Other, Italy
IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori- IRST S.r.l
Meldola, Other, Italy
Istituto Europeo di Oncologia
Milan, Other, Italy
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, Other, Italy
Fondazione Policlinico Universitario Agostino
Rome, Other, Italy
Hospital Universitario Vall d'Hebron
Barcelona, Other, Spain
L'Institut Catala d'Oncologia
L'Hospitalet de Llobregat, Other, Spain
Hospital Universitario Ramon y Cajal
Madrid, Other, Spain
HM Centro Integral Oncologico Clara Campal
Madrid, Other, Spain
Clinica Universidad de Navarra
Pamplona, Other, Spain
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Other, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.